

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Kindstar Globalgene Technology, Inc.**  
**康聖環球基因技術有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 9960)**

**VOLUNTARY ANNOUNCEMENT**  
**ACQUISITION OF APPROXIMATELY 11.38% EQUITY INTEREST IN**  
**THE TARGET COMPANY**

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of informing shareholders of the Company (“**Shareholders**”) and potential investors of the Group’s latest business developments.

**THE EQUITY TRANSFER AGREEMENTS**

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that on June 30, 2024 (after trading hours), Kindstar Global (Wuhan) Medical Esoteric Technology Co., Ltd. (“**Kindstar Global Wuhan**”) (a PRC consolidated entity whose financial results have been consolidated and accounted for as a subsidiary of the Company by virtue of variable interest entity structure (“**PRC Consolidated Entity**”)), three individuals (the “**Transferors**”) and certain other parties (the “**Other Parties**”) entered into a equity transfer agreement and a supplemental equity transfer agreement (collectively, the “**Equity Transfer Agreements**”), pursuant to which Kindstar Global Wuhan has agreed to conditionally acquire a total of approximately 11.38% equity interest in Beijing Bofurui Gene Diagnostic Technology Co., Ltd.\* (北京博富瑞基因診斷技術有限公司) (the “**Target Company**”) held by the Transferors (the “**Acquisition**”) at a total consideration of RMB31,876,000.

Upon completion of the Acquisition, the Target Company will not become a subsidiary of Kindstar Global Wuhan, and its financial results will not be consolidated into the Group’s consolidated financial statements.

**REASONS FOR AND BENEFITS OF THE ACQUISITION**

The Board is of the view that the Target Company, a leading enterprise in the field of transplantation esoteric testing and professional services in China, features its leading professional technology and stable sustainability. The Acquisition will be beneficial to the Company as it can further improve the Group’s strategic system of “comprehensive, systematic and advanced” esoteric testing; enhance the penetration rate, influence and customer service efficiency of the Group’s core testing technology in the transplantation market through industry synergy.

In view of the above, the Directors are of the view that the terms of the Equity Transfer Agreements and the Acquisition contemplated thereunder are fair and reasonable, and in the interests of the Company and the Shareholders as a whole.

## **LISTING RULES IMPLICATIONS**

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, the Transferors, the Target Company, the Other Parties and the respective ultimate beneficial owners of the foregoing are all third parties independent of the Company and its connected persons. Accordingly, the Acquisition does not constitute a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

As all applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the Acquisition are less than 5%, the Acquisition does not constitute a notifiable transaction under Chapter 14 of the Listing Rules. This announcement is made by the Company on a voluntary basis.

## **BASIC INFORMATION OF THE RELEVANT PARTIES**

### **The Company**

The Company is an exempted company with limited liability incorporated under the laws of the Cayman Islands on August 24, 2007. The Group is a leading independent clinical esoteric testing service provider in the PRC.

### **Kindstar Global Wuhan**

Kindstar Global Wuhan is a limited liability company established under the laws of the PRC on September 5, 2017. It is a PRC Consolidated Entity and is principally engaged in investment holding.

### **The Target Company**

The Target Company is a limited liability company established under the laws of the PRC on February 9, 2002, which is principally engaged in molecular immunoassay esoteric testing services, sales of medical devices and scientific research services in the field of transplantation medicine. The subsidiaries of the Target Company include Guangzhou Bofurui Medical Testing Co., Ltd.\* (廣州博富瑞醫學檢驗有限公司), Hangzhou Bofurui Medical Testing Laboratory Co., Ltd.\* (杭州博富瑞醫學檢驗實驗室有限公司) and Beijing Bofurui Medical Testing Laboratory Co., Ltd.\* (北京博富瑞醫學檢驗實驗室有限公司). As of the date of this announcement, the Target Company is held as to approximately 33.54% by Beijing Bofurui Technology Co., Ltd. (北京博富瑞科技有限公司) and approximately 22.72% by Mr. Liu Xiangdong; and Beijing Bofurui Technology Co., Ltd. is held as to approximately 89.49% by Mr. Liu Xiangdong.

### **Transferors**

Each of the Transferors is a PRC citizen. As of the date of this announcement, the Transferors collectively hold 13.66% equity interest in the Target Company.

**As the Acquisition is subject to certain conditions precedent being satisfied or waived, where applicable, it may not be completed eventually. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Kindstar Globalgene Technology, Inc.**  
康聖環球基因技術有限公司  
**HUANG Shiang**  
*Chairman*

Hong Kong, July 15, 2024

*As of the date of this announcement, the Board comprises Dr. HUANG Shiang, Mr. TU Zanbing and Ms. CHAI Haijie as executive Directors, Mr. HUANG Zuie-Chin, Mr. PENG Wei and Ms. HUANG Lu as non-executive Directors, and Dr. YAO Shanglong, Dr. XIA Xinping and Mr. GU Huaming as independent non-executive Directors.*

\* *For identification purposes only*